Pediatric asthma: an unmet need for more effective, focused treatments

Nikolaos G Papadopoulos (Corresponding Author), Adnan Čustović, Michael D. Cabana, Philip R. Lee, Sharon D. Dell, Antoine Deschildre, Gunilla Hedlin, Elham Hossny, Peter Le Souëf, Paolo M. Matricardi, Antonio Nieto, Wanda Phipatanakul, Paulo M. Pitrez, Petr Pohunek, Marcela Gavornikova, Xavier Jaumont, David B Price

Research output: Contribution to journalReview articlepeer-review

47 Citations (Scopus)
14 Downloads (Pure)


BACKGROUND: Despite remarkable advances in our understanding of asthma, there are still several unmet needs associated with the management of pediatric asthma.

METHODS: A two-day, face-to-face, meeting was held in London, United Kingdom, on 28th and 29th October 2017 involving a group of international expert clinicians and scientists in asthma management to discuss the challenges and unmet needs that remain to be addressed in pediatric asthma.

RESULTS: These unmet needs include a lack of clinical efficacy and safety evidence, and limited availability of non-steroid-based alternative therapies in patients <6 years of age. An increased focus on children is needed in the context of clinical practice guidelines for asthma; current pediatric practice relies mostly on extrapolations from adult recommendations. Furthermore, no uniform definition of pediatric asthma exists, which hampers timely and robust diagnosis of the condition in affected patients.

CONCLUSIONS: There is a need for a uniform definition of pediatric asthma, clearly distinguishable from adult asthma. Furthermore, guidelines which provide specific treatment recommendations for the management of pediatric asthma are also needed. Clinical trials and real-world evidence studies assessing anti-immunoglobulin E (IgE) therapies and other monoclonal antibodies in children <6 years of age with asthma may provide further information regarding the most appropriate treatment options in these vulnerable patients. Early intervention with anti-IgE and non-steroid-based alternative therapies, may delay disease progression, leading to improved clinical outcomes. This article is protected by copyright. All rights reserved.

Original languageEnglish
Pages (from-to)7-16
Number of pages10
JournalPediatric Allergy & Immunology
Issue number1
Early online date15 Nov 2018
Publication statusPublished - Feb 2019

Bibliographical note

The authors acknowledge Pascal Pfister for his support during the development of this manuscript. The authors also thank Gillian Lavelle PhD, of Novartis Product Lifecycle Services, Dublin, Ireland for providing medical writing support, which was funded by Novartis Pharma AG, Basel, Switzerland, in accordance with Good Publication Practice (GPP3) guidelines (


  • asthma management
  • omalizumab
  • pediatric asthma
  • unmet need
  • Humans
  • United Kingdom
  • Asthma/drug therapy
  • Glucocorticoids/therapeutic use
  • Omalizumab/adverse effects
  • Health Services Needs and Demand
  • Delivery of Health Care/methods
  • Adolescent
  • Anti-Asthmatic Agents/adverse effects
  • Child
  • Practice Guidelines as Topic


Dive into the research topics of 'Pediatric asthma: an unmet need for more effective, focused treatments'. Together they form a unique fingerprint.

Cite this